Engineers Gate Manager LP bought a new position in OraSure Technologies, Inc. (NASDAQ:OSUR) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 71,185 shares of the medical instruments supplier’s stock, valued at approximately $1,229,000. Engineers Gate Manager LP owned 0.12% of OraSure Technologies at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of OSUR. Louisiana State Employees Retirement System bought a new stake in OraSure Technologies in the 1st quarter worth approximately $287,000. Nationwide Fund Advisors grew its position in OraSure Technologies by 209.1% in the 1st quarter. Nationwide Fund Advisors now owns 144,922 shares of the medical instruments supplier’s stock worth $1,874,000 after purchasing an additional 98,034 shares during the period. Profund Advisors LLC bought a new stake in OraSure Technologies in the 1st quarter worth approximately $137,000. Great West Life Assurance Co. Can grew its position in OraSure Technologies by 2,066.8% in the 1st quarter. Great West Life Assurance Co. Can now owns 76,054 shares of the medical instruments supplier’s stock worth $982,000 after purchasing an additional 72,544 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its position in OraSure Technologies by 50.4% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 71,830 shares of the medical instruments supplier’s stock worth $929,000 after purchasing an additional 24,072 shares during the period. 92.12% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Anthony Zezzo II sold 72,916 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $21.26, for a total transaction of $1,550,194.16. Following the completion of the transaction, the executive vice president now owns 218,326 shares of the company’s stock, valued at $4,641,610.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Douglas A. Michels sold 290,495 shares of the firm’s stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $16.75, for a total transaction of $4,865,791.25. Following the transaction, the chief executive officer now directly owns 894,012 shares of the company’s stock, valued at approximately $14,974,701. The disclosure for this sale can be found here. In the last three months, insiders have sold 960,173 shares of company stock valued at $18,752,210. 6.40% of the stock is currently owned by corporate insiders.

Shares of OraSure Technologies, Inc. (NASDAQ OSUR) opened at 21.71 on Thursday. The company has a market cap of $1.29 billion, a P/E ratio of 40.13 and a beta of 1.57. The stock’s 50 day moving average is $20.14 and its 200-day moving average is $15.80. OraSure Technologies, Inc. has a 12 month low of $7.09 and a 12 month high of $22.15.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.02. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The firm had revenue of $40.18 million during the quarter, compared to analysts’ expectations of $36.54 million. During the same quarter last year, the company posted $0.07 earnings per share. The firm’s revenue was up 28.1% compared to the same quarter last year. On average, equities analysts forecast that OraSure Technologies, Inc. will post $0.48 EPS for the current year.

A number of brokerages have recently issued reports on OSUR. Jefferies Group LLC reissued a “buy” rating and set a $20.00 price objective on shares of OraSure Technologies in a research report on Tuesday. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Saturday, September 9th. Canaccord Genuity boosted their price objective on shares of OraSure Technologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. BidaskClub downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, Stephens reissued an “overweight” rating and set a $19.00 price objective (up previously from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $16.46.

COPYRIGHT VIOLATION WARNING: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/14/engineers-gate-manager-lp-takes-position-in-orasure-technologies-inc-osur.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.